+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Allergic Bronchopulmonary Aspergillosis Pipeline Insight, 2019

  • ID: 4835335
  • Drug Pipelines
  • 60 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Cipla
  • Genentech
  • Pfizer
  • Pulmatrix
  • Pulmocide
  • Teva Pharmaceuticals
  • MORE
Allergic Bronchopulmonary Aspergillosis (ABPA)

Overview:

Allergic Bronchopulmonary Aspergillosis (ABPA) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic Bronchopulmonary Aspergillosis pipeline landscape is provided which includes the disease overview and Allergic Bronchopulmonary Aspergillosis treatment guidelines. The assessment part of the report embraces, in depth Allergic Bronchopulmonary Aspergillosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Bronchopulmonary Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Allergic Bronchopulmonary Aspergillosis (ABPA) Understanding

Allergic bronchopulmonary aspergillosis is a form of lung disease that occurs in some people who are allergic to Aspergillus. With ABPA, this allergic reaction causes the immune system to overreact to Aspergillus leading to lung inflammation. ABPA causes bronchospasm (tightening of airway muscles) and mucus buildup resulting in coughing, breathing difficulty and airway obstruction. Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to Aspergillus species A. fumigatus that occurs almost exclusively in patients with asthma or, less commonly, cystic fibrosis. Immune responses to Aspergillus antigens cause airway obstruction and, if untreated, bronchiectasis and pulmonary fibrosis. Symptoms and signs are those of asthma with the addition of productive cough and, occasionally, fever and anorexia. Diagnosis is suspected based on history and imaging tests and confirmed by Aspergillus skin testing and measurement of IgE levels, circulating precipitins, and A. fumigatus-specific antibodies. Treatment is with corticosteroids and, in patients with refractory disease, itraconazole.

Allergic Bronchopulmonary Aspergillosis (ABPA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Allergic Bronchopulmonary Aspergillosis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Allergic Bronchopulmonary Aspergillosis (ABPA) pipeline report covers 3+ companies. Some of the key players include Pulmatrix Inc. (PUR1900), Cipla (Prednisolone), Pulmocide (PC945) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Allergic Bronchopulmonary Aspergillosis (ABPA) Analytical Perspective

In-depth Allergic Bronchopulmonary Aspergillosis (ABPA) Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Allergic Bronchopulmonary Aspergillosis (ABPA) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Allergic Bronchopulmonary Aspergillosis (ABPA) report provides an overview of therapeutic pipeline activity for Allergic Bronchopulmonary Aspergillosis (ABPA) across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Allergic Bronchopulmonary Aspergillosis (ABPA) therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Allergic Bronchopulmonary Aspergillosis (ABPA) Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Allergic Bronchopulmonary Aspergillosis (ABPA)
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Allergic Bronchopulmonary Aspergillosis (ABPA) to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Allergic Bronchopulmonary Aspergillosis (ABPA) R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Allergic Bronchopulmonary Aspergillosis (ABPA) in licensing and out licensing strategies by identifying prospective partners with progressing projects for Allergic Bronchopulmonary Aspergillosis (ABPA) to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Please note: The report will be dispatched within 2-3 days
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Cipla
  • Genentech
  • Pfizer
  • Pulmatrix
  • Pulmocide
  • Teva Pharmaceuticals
  • MORE
1. Report Introduction

2. Allergic Bronchopulmonary Aspergillosis (ABPA)
2.1. Allergic Bronchopulmonary Aspergillosis (ABPA) Disease Overview
2.2. Allergic Bronchopulmonary Aspergillosis (ABPA) History
2.3. Allergic Bronchopulmonary Aspergillosis (ABPA) Symptoms
2.4. Allergic Bronchopulmonary Aspergillosis (ABPA) Causes
2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) Pathophysiology
2.6. Allergic Bronchopulmonary Aspergillosis (ABPA) Diagnosis
2.6.1. Diagnostic Guidelines

3. Allergic Bronchopulmonary Aspergillosis (ABPA) Current Treatment Patterns
3.1. Treatment Guidelines

4. Allergic Bronchopulmonary Aspergillosis (ABPA)- Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Allergic Bronchopulmonary Aspergillosis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Allergic Bronchopulmonary Aspergillosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Allergic Bronchopulmonary Aspergillosis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono/Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA

5. Allergic Bronchopulmonary Aspergillosis Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products

6. Allergic Bronchopulmonary Aspergillosis -Products Analysis
6.1. Product Profiles
6.1.1. PUR1900: Pulmatrix Inc.
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Prednisolone : Cipla
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. PC945: Pulmocide
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table

7. Recent Technologies

8. Allergic Bronchopulmonary Aspergillosis Key Companies
8.1. Pulmatrix
8.2. Pulmocide
8.3. Cipla

9. Allergic Bronchopulmonary Aspergillosis Key Products
9.1. Itraconazole inhaled
9.2. PC 945
9.3. Prednisolone

10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation

11. Allergic Bronchopulmonary Aspergillosis - Unmet Needs

12. Allergic Bronchopulmonary Aspergillosis - Future Perspectives

13. Appendix

14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pulmatrix
  • Pulmocide
  • Genentech
  • Pfizer
  • Teva Pharmaceuticals
  • Cipla
Note: Product cover images may vary from those shown
Adroll
adroll